Loading clinical trials...
Loading clinical trials...
The purpose of this study is to characterize the safety and tolerability and efficacy of multiple ascending doses of etelcalcetide in hemodialysis patients for the treatment of secondary hyperparathyr...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
KAI Pharmaceuticals
NCT03633708 · Secondary Hyperparathyroidism, Chronic Kidney Disease
NCT04922892 · Secondary Hyperparathyroidism;Parathyroidectomy
NCT06434961 · Secondary Hyperparathyroidism
NCT04064827 · Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
NCT02859896 · Secondary Hyperparathyroidism-Chronic Kidney Disease
Azusa, California
Costa Mesa, California
Lynwood, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions